Individuals who enroll in clinical trials do so with the belief that their participation will help to advance medical science. However, many trials are designed, conducted, and reported in ways that stymie this objective, a problem that can be called “uninformativeness.” From the perspective of researchers, this is a form of research inefficiency.1 But from the perspective of participants, preventable uninformativeness is a serious breach of trust and a violation of research ethics.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Zarin DA, Goodman SN, Kimmelman J. Harms From Uninformative Clinical Trials. JAMA. 2019;322(9):813–814. doi:10.1001/jama.2019.9892
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: